ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Full-time Co-op at Kernal Biologics, Inc. - ApplyBlast

Full-time Co-op

Kernal Biologics, Inc.

17 days ago

Boston, Massachusetts, United States

Onsite

Internship

Intern

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Kernal Bio is seeking a highly motivated Co-op to join the LNP team, contributing to the advancement of next-generation mRNA-LNP therapeutics through production, formulation, and analytical characterization. The role offers hands-on experience across multiple manufacturing functions and collaboration with experienced scientists and engineers. The position also involves assisting with authoring and reviewing key documentation such as protocols, batch records, and SOPs.

Responsibilities

Support routine mRNA and LNP production, purification, and analytical testing
Assist with LNP formulation, optimization, and process development
Maintain human and murine cell lines and quantify expression by flow cytometry

Skills

Qualifications

B.S. or M.S. student in Biology, Biomedical Engineering, Molecular Biology, Biochemistry, Pharmaceutical Sciences, Analytical Chemistry, or a related field

About Kernal Biologics, Inc.

kernalbio.com

Headquarters

Cambridge, Massachusetts, United States

Company Size

11-50 employees

Founded

2016

View Profile

Kernal Biologics is an onco-selective mRNA therapeutics company based in Cambridge, MA that develops in vivo cell therapies by programming cells directly inside the body through targeted delivery and selective translation. Their platform uses state-of-the-art AI models to ensure selective mRNA translation in target cells, enabling scalable in vivo CAR-T therapies for patients with cancer and auto-immune diseases. Kernal overcomes the manufacturing, cost, and accessibility limitations of current ex vivo cell therapies and has received up to $48 million in funding from ARPA-H to advance its pipeline.